Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management

Journal of the National Cancer Institute

Volumn 93, Issue 8, 2001, Pages 630-635

  Greco, Marco ^a   Crippa, Flavio ^a   Agresti, Roberto ^a   Seregni, Ettore ^a   Gerali, Alberto ^a   Giovanazzi, Riccardo ^a   Micheli, Andrea ^a   Asero, Salvatore ^a   Ferraris, Cristina ^a   Gennaro, Massimiliano ^a   Bombardieri, Emilio ^a   Cascinelli, Natale ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DIAGNOSTIC ACCURACY; EVALUATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 0035906212     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.8.630     Document Type: Article

References (41)

1. Is axillary dissection necessary for T1 carcinoma of the breast?
2. Reappraisal of the role of the axillary lymph node dissection in the conservative treatment of breast cancer
3. Axillary lymph node dissection for T1 a breast carcinoma. Is it indicated?
4. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection
5. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie
6. Prognosis based on primary breast carcinoma instead of pathological nodal status
7. Breast cancer patients treated without axillary surgery: Clinical implication and biologic analysis
8. Sentinel lymph node detection and imaging
9. Lymphatic mapping and sentinel node biopsy in breast cancer
10. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
11. Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series
12. The sentinel node in breast cancer-a multicenter validation study
13. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer
14. Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection
15. Sentinel node biopsy in the staging of breast cancer
16. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center
17. Sentinel-lymph-node biopsy for breast cancer-not yet the standard of care
18. A brief history of positron emission tomography (PET)
19. PET in breast cancer
20. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
21. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation
22. Approximate is better than exact for interval estimation of binomial proportions
23. Two-sided confidence intervals for the single proportion: Comparison of seven methods
24. Sg 119. Improved confidence interval for binomial proportions
25. Laboratory and clinical research in breast cancer-a personal adventure: The David A. Karnovsky memorial lecture
26. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis
27. Polychemotherapy for early breast cancer: An overview of the randomised trials
28. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
29. 18F]fluoro-2-deoxy-d-glucose
30. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-d-glucose
31. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
32. Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-d-glucose (FDG) PET
33. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose
34. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-d-glucose
35. PET instrumentation: What are the limits?
36. Diagnostic value of positron emission tomography for detecting breast cancer
37. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-d-glucose PET
38. Serum glucose: Effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma
39. 18F]fluorodeoxyglucose (FDG) uptake in cancer: A PET study in liver metastases from colorectal carcinomas
40. The sentinel node in breast cancer: Implication for adjuvant treatment?
41. 18F]-d-glucose